This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. This is the industry’s definitive antigen specific drugdevelopment forum.
The Non-Small Cell Lung Cancer (NSCLC) DrugDevelopment Summit is the definitive industry-led forum for drugdevelopment in the largest solid tumor indication. The post Non-Small Cell Lung Cancer DrugDevelopment Summit appeared first on. View the event guide now for more details!
Pick the brains of 140+ senior level drugdevelopers across industry and academia at the physical return of the only meeting dedicated to overcoming challenges in biomarker understanding, disease selection and clinical translation in inflammasome-centered drugdevelopment.
Potential of nipocalimab for HDFN “Nipocalimab is the only drug in development with the potential to treat a variety of alloimmune diseases that affect the foetus such as foetal/neonatal alloimmune thrombocytopenia and immune-mediated congenital heart block,” lead study investigator Dr Kenneth Moise Jr. ,
As well as presenting recent findings from the pivotal AFM13-104 study, Andreas also reflects on the challenges encountered and conquered in developing Affimed’s innate cell engager, Acimtamig, which targets CD30 on lymphoma cells and CD16A on NK cells. at the Hannover MedicalSchool, Germany, and spent his career as a practicing oncologist.
In an email to this news service, João Conde, PhD, professor at NOVA MedicalSchool, Universidade NOVA de Lisboa, said advances like the mRNA vaccines serve as a testament to the breakthroughs made by science over decades of research at the junction of genetics and nanomedicine.
“I’m slowly running out of options,” said Young, 62, who in November began receiving a five-month series of shots at a clinic near her San Francisco home; the vaccine is designed to teach her immune cells to recognize and combat tumors.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content